News Column

Researchers' Work from Kurume University Focuses on Peptide Vaccines (Personalized Peptide Vaccine for Treatment of Advanced Cancer)

July 7, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Data detailed on Biotechnology have been presented. According to news reporting from Fukuoka, Japan, by NewsRx journalists, research stated, "The field of cancer immunotherapy has moved forward drastically in the past 20 years, since many tumorassociated antigens (TAA) have been identified. Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the complexity and diversity of tumor cell characteristics and host immune cell repertoires seem to limit the therapeutic efficacy of this treatment modality."

The news correspondents obtained a quote from the research from Kurume University, "Considering the diversity of immune responses against heterogeneous tumor cells, tailored selections of vaccine antigens appropriate for individual patients could be a rational approach for developing effective cancer vaccines. We have developed a novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides were selected based on the pre-existing host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV."

According to the news reporters, the research concluded: "In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified."

For more information on this research see: Personalized Peptide Vaccine for Treatment of Advanced Cancer. Current Medicinal Chemistry, 2014;21(21):2332-2345. Current Medicinal Chemistry can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Medicinal Chemistry - www.benthamscience.com/cmc/index.htm)

Our news journalists report that additional information may be obtained by contacting T. Sasada, Kurume University, Sch Med, Dept. of Urol, Kurume, Fukuoka 8300011, Japan. Additional authors for this research include A. Yamada, M. Noguchi and K. Itoh (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Japan, Fukuoka, Oncology, Vaccination, Immunization, Cancer Vaccines, Peptide Vaccine, Biological Therapy, Biological Products

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters